CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

FDA Grants BCMA CAR T-Cell Therapy Breakthrough Designation in Myeloma

November 17th 2017

The FDA has granted the the anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy bb2121 a breakthrough therapy designation for previously treated patients with relapsed/refractory multiple myeloma.

CAR T-Cell Therapy Approval Starts New Path in Childhood Leukemia

November 16th 2017

Sarah K. Tasian, MD, discusses the success of CAR T-cell therapy, as well as novel agents and immunotherapies that appear promising in the treatment of children with leukemia.

Dr. Epperla on CAR T-Cell Therapy in MCL

November 15th 2017

Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University (OSU) Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with mantle cell lymphoma (MCL).

Questions Remain With CAR-T's, Checkpoints in Hematologic Malignancies

November 14th 2017

Leo I. Gordon, MD, discusses promising advances and lingering challenges with novel treatments for patients with hematologic malignancies.

JCAR015 Experience Informs Future CAR-T Studies

November 11th 2017

The high rates of cerebral edema seen with JCAR015 in the phase II ROCKET trial were attributed to early and rapid chimeric antigen receptor (CAR)-modified T-cell expansion and a rise in interleukin-15 levels, a finding that could help inform future CAR T-cell usage.

Dr. Shah on Toxicites Associated With CAR T-Cell Therapy

November 10th 2017

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, comments on the toxicities associated with using chimeric antigen receptor (CAR) T-cell therapy in patients with leukemia.

Combinations Required to Further Advance Adoptive T-Cell Therapy

November 10th 2017

A variety of adoptive T-cell therapy strategies have shown promise in clinical studies with recent FDA approvals granted to CAR-modified T-cell therapies, representing the potential for future combination strategies.

FDA Lifts Holds on "Off-the-Shelf" CAR-T Trials

November 7th 2017

The FDA today lifted clinical holds placed on 2 phase I trials investigating a gene-edited allogeneic CAR T-cell therapy known as UCART123.

Tisagenlecleucel Submitted for European Approval for ALL, DLBCL

November 7th 2017

The European Medicines Agency (EMA) has received a Marketing Authorization Application (MAA) for tisagenlecleucel (Kymriah) for 2 forms of advanced lymphoma.

Dr. Maloney on Future Treatment With CAR T-Cell Therapy

November 3rd 2017

David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the future treatment landscape for chimeric antigen receptor (CAR) T-cell therapy.

Personalized Medicine Moving to Forefront of Hematologic Malignancies

November 3rd 2017

Edward A. Stadtmauer, MD, sheds light on the future of chimeric antigen receptor T-cell therapy, systemic therapeutic advances in the field of acute myeloid leukemia, and remaining challenges in the multiple myeloma paradigm.

Dr. Stadtmauer on Current Challenges With Multiple Myeloma

November 3rd 2017

Expert Highlights CAR T-Cell Breakthroughs

November 1st 2017

David G. Maloney, MD, PhD, discusses the progress made with CAR T cells, as well as the challenges that still exist in the use of this therapy.

Novartis Submits sBLA for Tisagenlecleucel in Adults With Relapsed/Refractory DLBCL

October 31st 2017

Novartis has filed a supplemental biologics license application with the FDA to expand the indication for tisagenlecleucel (Kymriah) to include adults with relapsed/refractory DLBCL who are ineligible for ASCT.

DLBCL Landscape Shifts Dramatically With Axicabtagene Ciloleucel FDA Approval

October 24th 2017

Reem Karmali, MD, discusses ongoing key trials of CAR T-cell therapy, the chronic safety concerns with the treatment, and what combinations have the most potential.

Dr. Karmali on the Future of CAR T-Cell Therapy in DLBCL

October 23rd 2017

Reem Karmali, MD, Feinberg School of Medicine, Northwestern University, discusses the future of chimeric antigen receptor (CAR) T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

Dr. Gordon on the Concerns of CAR T-Cell Therapy

October 23rd 2017

Leo I. Gordon, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, discusses the concerns of chimeric antigen receptor (CAR) T-cell therapy.

Dr. Karmali Discusses Toxicites Associated With CAR T-Cell Therapies

October 20th 2017

Reem Karmali, MD, assistant professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses the toxicities associated with the use of chimeric antigen receptor (CAR) T-cell therapies.

CAR T-Cell Approvals Leading Landscape of Hematologic Cancers

October 20th 2017

Andre Goy, MD, discusses the recent success with CAR T-cell therapy, and what is on the horizon for this therapeutic option across hematologic malignancies.

FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma

October 19th 2017

The FDA has approved the CD19-directed CAR T-cell therapy axicabtagene ciloleucel as a treatment for adults with relapsed or refractory non-Hodgkin lymphoma.